Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019.
“I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspective and medical leadership to generate more data on the uniqueness of Iluvien’s ability to help patients maintain vision longer with fewer injections,” said Rick Eiswirth, President and CEO. “Additionally, his expertise in neuroprotection and neuroinflammation will bring a fresh perspective to our vision of becoming a first-class retina organization.”
Dr. Kaba was appointed Chief Medical Officer, a new position at Alimera Sciences, as of April 3, 2019, and will be a member of the company’s executive management team. Dr. Kaba will be responsible for directing Alimera’s global medical strategy behind current and future projects. Functions under Dr. Kaba’s oversight will include medical affairs, pharmacovigilance, medical information, quality, clinical operations, and regulatory.
Dr. Kaba is a board-certified neurologist with over 15 years of pharmaceutical industry experience leading diverse teams and global projects. Prior to joining Alimera, Dr. Kaba served as Chief Medical Officer at Cortexyme where he was responsible for formulating and executing regulatory and clinical development strategies. Prior to this he was Global Head of Clinical Development and Medical Affairs at Osmotica Pharmaceuticals where he led the development of new products and supported marketed drugs, and Vice President of Medical Affairs at Medpace where he was instrumental in expanding claims and messaging in the neuroscience therapeutic area.
Prior to joining the pharmaceutical industry, Dr. Kaba held multiple academic positions at the University of Texas MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Emory University, and maintained a neurology/MS private practice. Dr. Kaba completed his medical degree at Damascus University School of Medicine, and his neurology training at the State University of New York at Buffalo. He also completed fellowship training in neuro-ophthalmology and neuro-immunology (multiple sclerosis) at the State University of New York at Buffalo, and in neuro-oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Kaba is board-certified by the American Board of Psychiatry and Neurology.